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Abstract
Antiestrogen resistance in estrogen receptor positive (ER+) breast cancer is associated with increased expression and activity
of insulin-like growth factor 1 receptor (IGF1R). Here, a kinome siRNA screen has identiﬁed 10 regulators of IGF1R-
mediated antiestrogen with clinical signiﬁcance. These include the tamoxifen resistance suppressors BMPR1B, CDK10,
CDK5, EIF2AK1, and MAP2K5, and the tamoxifen resistance inducers CHEK1, PAK2, RPS6KC1, TTK, and TXK. The p21-
activated kinase 2, PAK2, is the strongest resistance inducer. Silencing of the tamoxifen resistance inducing genes,
particularly PAK2, attenuates IGF1R-mediated resistance to tamoxifen and fulvestrant. High expression of PAK2 in ER+
metastatic breast cancer patients is correlated with unfavorable outcome after ﬁrst-line tamoxifen monotherapy. Phospho-
proteomics has deﬁned PAK2 and the PAK-interacting exchange factors PIXα/β as downstream targets of IGF1R signaling,
which are independent from PI3K/ATK and MAPK/ERK pathways. PAK2 and PIXα/β modulate IGF1R signaling-driven
cell scattering. Targeting PIXα/β entirely mimics the effect of PAK2 silencing on antiestrogen re-sensitization. These data
indicate PAK2/PIX as an effector pathway in IGF1R-mediated antiestrogen resistance.
Introduction
More than 70% of breast cancers are estrogen receptor
positive (ER+) and dependent on estrogen for growth and
progression [1]. Antiestrogen therapy by tamoxifen or ful-
vestrant has been the front-line treatment for ER+ breast
cancers [2, 3]. Despite the effectiveness at ﬁrst, around 50%
of the treated breast cancers will become antiestrogen-
resistant [4, 5]. Antiestrogen resistance is attributed to loss
of ER expression or function in breast cancers where ER
does not actually play a central role [6, 7]. Additionally,
resistant breast cancers often show upregulated signaling of
receptor tyrosine kinases, including epidermal growth factor
receptor [8, 9], HER2 [10, 11] and insulin-like growth
factor 1 receptor (IGF1R) [12–14].
High IGF1R expression is associated with migration and
invasion of breast cancer and metastasis-free survival of ER
+ breast cancer patients [15–19]. IGF1R activation by
insulin-like growth factor 1 (IGF-1) promotes cell death
resistance of ER+ breast cancer cells [17]. During treatment
of breast cancer, IGF1R expression is upregulated, resulting
in resistance to conventional breast cancer therapies and
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poor outcome [20]. Several high-throughput screening stu-
dies have mapped IGF1R as a candidate target to re-
sensitize tamoxifen resistant breast cancer cells [12, 21, 22].
We and others have demonstrated that IGF1R signaling can
confer resistance to antiestrogen treatment regardless of ER
activity [12, 14]. IGF1R is coupled to multiple downstream
pathways and, besides PI3K/AKT and MAPK/ERK sig-
naling [14], it is unresolved which of these contribute to
antiestrogen resistance.
Here we performed a small interfering RNA (siRNA)
screen targeting all kinases and phosphatases to unravel
signaling cascades underlying IGF1R-mediated antiestro-
gen resistance. For identiﬁed candidate targets to combat
resistance, association was determined with clinical out-
come of metastatic ER+ breast cancers treated with ﬁrst-line
of tamoxifen monotherapy. Our results reveal PAK2, as
well as the PAK-interacting exchange factors PIXα/β, as a
critical determinant in IGF1R-mediated antiestrogen resis-
tance with signiﬁcant clinicopathological correlation to
tamoxifen resistance development.
Results
Kinome siRNA screen of IGF1R-mediated tamoxifen
resistance
MCF7/IGF1R cells with ectopic IGF1R expression (Sup-
plementary Fig. 1A) remain sensitive to the antagonistic
effects of antiestrogens 4-hydroxytamoxifen (4OHT) and
fulvestrant (FUL) against estrogen 17β-estradiol (E2), but
are highly resistant when stimulated with IGF-1 (Supple-
mentary Fig. 1B) [14]. Using this cell model, we performed
a human kinase and phosphatase siRNA primary screen
under the tamoxifen resistance condition, as schemed
(Supplementary Fig. 2A). Replica screens displayed high
reproducibility (Fig. 1a, b). Z-score ranking revealed 66
kinases and 8 phosphatases whose knockdown increased
cell proliferation, and 79 kinases and 21 phosphatases
whose targeting inhibited cell proliferation (Fig. 1a, b and
Supplementary Table 1). We classiﬁed the former genes as
tamoxifen resistance suppressors, meaning that their
expression or signaling may suppress tamoxifen resistance,
and the latter as tamoxifen resistance inducers, meaning that
their expression or signaling induces tamoxifen resistance.
Next, we validated all tamoxifen resistance inducers and
a few top ranked or clinically relevant tamoxifen resistance
suppressors (as mentioned below), for their on-target
silencing by SMARTpool siRNA and its 4 deconvoluted
siRNAs and for their functional relevance to tamoxifen
resistance status, compared to E2 and IGF-1 stimulation
(Supplementary Fig. 2B). All validated 114 hits displayed
positive effect under the resistance condition
(Supplementary Fig. 3A). The majority of hits were on-
target (Fig. 1c and Supplementary Fig. 4). Fifty-one hits
were common to all conditions, while others were speciﬁc
to one or two conditions (Fig. 1d and Supplementary Fig.
4). Particularly, several positive hits showed no effect or an
opposite effect under IGF-1 or E2 condition, implying their
distinct roles in IGF1R-mediated tamoxifen resistance
(Supplementary Fig. 3B and C). These included Abl1,
CKM, MAP4K3, NTRK2, PAK2, RPS6KC1, SAST, SSTK,
TAF1, PPP2R5D, and TPTE2.
Clinical relevance of IGF1R-mediated tamoxifen
resistance hits
To evaluate the clinical relevance of the screened hits
(Supplementary Table 1), we analyzed them as continuous
variable in our established Agilent 44k oligo-array dataset
of 101 ER+ metastatic breast cancer (MBC) patients treated
with ﬁrst-line tamoxifen monotherapy [23, 24]. All candi-
date genes in this dataset could be analyzed for an asso-
ciation with treatment outcome. The results revealed 10 hits
with high relevance to poor treatment outcome and pro-
gression free survival (PFS) (Fig. 2a). Signiﬁcantly, the
predicted hazard ratio (HR) is low in patients expressing
tamoxifen resistance suppressors BMPR1B, CDK10, CDK5,
EIF2AK1, and MAP2K5, and high in those expressing
tamoxifen resistance inducers CHEK1, PAK2, RPS6KC1,
TTK, and TXK. Furthermore, we evaluated these 10 hits for
their prognostic values with the natural course of disease in
221 ER+ lymph node negative (LNN) breast cancer patients
who did not receive any adjuvant systemic treatment [25].
The results demonstrated that expression levels of
BMPR1B, CDK10, EIF2AK1, MAP2K5, CHEK1, and
PAK2, were not prognostic in this subset (Fig. 2b), showing
a relationship only with tamoxifen therapy response.
Targeting of tamoxifen resistance inducing hits with
clinical relevance restores antiestrogen sensitivity
These 10 hits were on-target under tamoxifen resistance
condition, displaying differential effects under IGF-1 or
E2 stimulative condition (Fig. 1e). Next, we established
their dose-response relationships to 4OHT (Fig. 3a) and
FUL (Fig. 3b) in combination with E2 and IGF-1. Com-
pared to siRNA control (siCtrl), silencing of each tamoxifen
resistance suppressor enhanced proliferation by IGF-1 and
E2, above the siCtrl levels where the resistance remains. In
contrast, silencing of the tamoxifen resistance inducer
CHEK1, TTK, or TXK signiﬁcantly reduced IGF-1 and E2
induced proliferation, largely below the siCtrl levels. Of
interest, targeting the inducer PAK2 or RPS6KC1 restored
the dose-dependent response to 4OHT and FUL, in the
presence of IGF-1.
Y. Zhang et al.
Fig. 1 Identiﬁcation of determinants in IGF1R-mediated tamoxifen
resistance by kinome siRNA Screen. a Primary kinase and b phos-
phatase siRNA screen of MCF7/IGF1R cells under tamoxifen resis-
tance condition where 4OHT (4-hydroxytamoxifen, 1 μM), E2 (17β-
estradiol, 1 nM) and IGF-1 (insulin-like growth factor 1, 100 ng/ml)
were given. Spearman correlation coefﬁcient R 2 values showed
reproducibility of replica screens. The hits for tamoxifen resistance
suppressors (Z>mean+ 1.5× SD, P< 0.05; in red) and inducers (Z
<mean - 1.5× SD, P< 0.05; in blue) were ranked by Z score plot and
numbered in pie charts. siRNAs targeting PTEN, AKT1, and MAPK1,
the known regulators in IGF1R-mediuated antiestrogen resistance [14],
were used as functional positive controls (Supplementary Figs. 1C and
D). The targeting effects of siPten (increasing proliferation), siAKT1
and siERK2 (decreasing proliferation), and the non-targeting effect of
negative control siCtrl were positioned in the Z score plots. c Vali-
dation screen of IGF1R-mediated tamoxifen resistance hits. Effects of
single siRNAs (siRNA_1, _2, _3 and _4) targeting 114 hits were
validated under tamoxifen resistance condition (I) 4OHT+ E2+ IGF-
1, compared to IGF-1 (II) and E2 (III) stimulation conditions. d The
number of hit siRNAs showing on-target effects under condition I, II
and III. e Comparison of SMARTpool siRNA and single siRNA_1,
_2, _3 and _4 targeting effects on 10 hits, which have clinical rele-
vance (Fig. 2a), under condition I, II and III in repeated experiment.
Values were derived from triplicate samples. Data were expressed as
mean± SD
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PAK2 is a target in IGF1R-mediated antiestrogen
resistance
Our transcriptomic data revealed the high expression of
PAK2 in both parental MCF7 and the established MCF7/
IGF1R cells, compared to any other PAK family members,
suggesting a critical role for PAK2 in these cells (Supple-
mentary Fig. 5A-B). Silencing of PAK2 (siPAK2), but none
of the other PAK members that are expressed in the MCF7/
IGF1R cells, PAK1, PAK4 and PAK6 (Supplementary Fig.
5C-D), inhibited cell proliferation signiﬁcantly under
tamoxifen resistance condition, less so in IGF-1 stimulation
or not at all under E2 condition (Fig. 1e), and restored
antiestrogen dose-responses (Fig. 3a, b). PAK2 predicated
the highest HR in tamoxifen-treated patients (Fig. 2a),
leading to poor survival (Fig. 4a). These results let us ﬁrst
focus on the potential role of PAK2, p21 protein (Cdc42/
Rac)-activated kinase 2, in IGF1R-mediated antiestrogen
resistance.
PAK2 on-target silencing re-sensitized MCF7/IGF1R
cells (Fig. 4b). Similar to siCtrl, siPAK2 allowed 4OHT and
FUL to antagonize E2 through a dose range, and did not
signiﬁcantly inﬂuence IGF-1-stimulated proliferation. Yet,
siPAK2 declined the proliferation of the resistant cells
under 4OHT or FUL dose-range with E2 plus IGF-1,
reaching similar levels under 4OHT/E2 or FUL/E2 antag-
onizing condition (Fig. 4c).
Lentiviral shRNA-mediated PAK2 stable knockdown in
MCF7/IGF1R cells, shPAK2_1 and shPAK2_2, did not
interfere with ER expression (Fig. 4d), E2 and IGF-1 sti-
mulated proliferation, or the antagonistic effects of 4OHT
and FUL on E2 (Supplementary Fig. 6). Nonetheless, while
IGF-1 provoked resistance in shRNA control (shCtrl) cells,
the resistant phenotype was drastically abolished in
shPAK2 cells (Supplementary Fig. 6) in 4OHT and FUL
concentration-dependent manners (Fig. 4e). As expected,
rescue of PAK2 expression in shPAK2 cells (Fig. 4f) ren-
dered the cells resistant to 4OHT and FUL (Fig. 4g). These
results indicated a pivotal role of PAK2 in controlling
IGF1R-mediated antiestrogen resistance.
PAK2 acts downstream of IGF1R signaling
independently from PI3K/AKT and MAPK/ERK
pathways
Relatively little is reported about activation of PAK sig-
naling in response to IGF-1 stimulation. To decipher IGF-1/
IGF1R assembled signaling networks, we performed a
Stable-Isotope Labeling by Amino Acids in Cell Culture
(SILAC)-based quantitative phospho-proteomics, as
schemed (Fig. 5a). Quantitative SILAC-based analysis
revealed that a number of components in IGF-1 and PAK
signaling were highly phosphorylated upon IGF-1 stimu-
lation (Fig. 5b). Ingenuity Pathway Analysis (IPA) plotted
out the crosstalk between the IGF-1 and PAK signaling
networks, where the signaling components ATM, MAP2K1,
MAP2K2, MAPK1, MAPK3, PIK3C2A, PXN, RAF1, SHC1,
and SOS1 were activated (Fig. 5c).
IGF-1 stimulation induced the phosphorylation of
numerous proteins/kinases that regulate cell proliferation,
growth and survival programs downstream of IGF1R sig-
naling pathway as mapped by IPA (Fig. 6a.). These kinases
mostly contributed as inducers to IGF1R-mediated tamox-
ifen resistance, including IGF1R, PI3K catalytic subunits
Fig. 2 Clinical relevance of 10 IGF1R-mediated tamoxifen resistance
hitsThe hazard ratios of the 10 hits are indicated by blue boxes and
their 95% conﬁdence intervals (95% CI) are represented by blue
horizontal lines. The P-value is shown for those signiﬁcant. a The 10
hits and the relationship with PFS in 101 breast cancer patients with
metastatic disease treated with ﬁrst-time tamoxifen monotherapy,
when analyzed as continuous variable. Hits in red, tamoxifen resis-
tance suppressors, with low Hazard Ratio (HR< 1). Hits in blue,
tamoxifen resistance inducers, with high HR (>1). b The 10 hits and
the relation with metastasis free survival in 221 ER+ breast cancer
patients who did not receive any adjuvant systemic therapy. This
patient cohort has been described by us previously [25]
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(PIK3CA and PIK3C2G), PDK1, AKT1, p70S6Ks
(RPS6KA2, RPS6KB1 and RPS6KC1), Raf1 and MAPK1
(Supplementary Fig. 5E). Importantly, SILAC spectra
revealed PAK2 phosphorylation at Ser141 (Fig. 6b). This
IGF-1-stimulated PAK2 phosphorylation was rapid and
constant (Fig. 6c and Supplementary Fig. 7A). IGF1R
kinase inhibitor BMS-538924 blocked PAK2
phosphorylation (Fig. 6d, left panels), conﬁrming
PAK2 signaling in IGF-1/IGF1R axis.
PAK signaling is linked to Grb2-Raf-ERK and PI3K/
AKT (Fig. 6a) [26–30], the two canonical routes down-
stream of receptor tyrosine kinase signaling transduction,
which are interrelated with IGF-1 and PAK signaling net-
works (Fig. 5c). We showed here that PAK2,
Fig. 3 Targeting effects on antiestrogen dose-responses of the IGF1R-
mediated tamoxifen resistance hits with clinical relevance. a 4OHT
and b FUL dose-response curves of siRNA silenced hits. FUL,
fulvestrant. DMSO, vehicle control. E2, 1 nM; IGF-1, 100 ng/ml.
Proliferation values were relative to siCtrl under DMSO control.
Values were derived from triplicate samples. Data were expressed as
mean± SD
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simultaneously with AKT and ERK, was activated by IGF-
1 stimulation (Supplementary Fig. 7A). While siPAK2 or
shPAK2 depletion did not eliminate ERK and AKT phos-
phorylation (Fig. 6e), MEK inhibitors (U0126, PD-184352
and AZD6244) and PI3K/AKT inhibitors (BEZ235 and
PI103) had no effect on PAK2 activation (Fig. 6d, middle
and right panels). Similarly, AKT silencing did not inhibit
IGF-1-stimulated PAK2 phosphorylation (Supplementary
Fig. 4 Targeting of tamoxifen resistance inducer PAK2 abrogates
IGF1R-mediated antiestrogen resistance. a Kaplan-Meier survival
curve for PFS in relation to PAK2 RNA expression level in metastatic
breast cancers treated with ﬁrst-line tamoxifen monotherapy, showing
the poor survival in 75 patients with high level of PAK2. b Inhibitory
effects of PAK2 SMARTpool and single siRNAs on PAK2 expression
and proliferation under tamoxifen resistance condition 4OHT (1 µM)
+ E2 (1 nM)+ IGF-1 (100 ng/ml). c Response curves of siPAK2,
compared to siCtrl, to dose-ranged 4OHT or FUL with E2 (1 nM) and/
or IGF-1 (100 ng/ml), as indicated. Proliferation values were relative to
siCtrl under DMSO control. d Lentivirus-mediated small hairpin RNA
(shRNA) stable knockdown of PAK2 in MCF7/IGF1R shPAK2_1 and
shPAK2_2 cells, compared to endogenous PAK2 in shRNA control
(shCtrl) cells. e Dose-dependent responsiveness of shPAK2_1 and
shPAK2_2 cells to 4OHT and FUL under indicated conditions, com-
pared to shCtrl control cells. Proliferation values were relative to
DMSO control. f PAK2 cDNA expression in shPAK2_1 cells. g
Recurrent resistance of shPAK2 cells with rescued PAK2 cDNA
expression to 4OHT and FUL under indicated conditions, compared to
pcDNA vector transfected shPAK2 cells. Proliferation values were
relative to DMSO control. Values were derived from triplicate sam-
ples. Data were expressed as mean± SD
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Fig. 7B). These results delineated that PAK2 signaling
deviates from PI3K/AKT and MAPK/ERK pathways in
IGF-1/IGF1R axis.
PAK2 suppresses the onset of apoptosis in IGF1R-
mediated antiestrogen resistance
PAKs play essential roles in cell-cycle progression and
apoptosis prevention [26, 28, 31]. Next, we examined
whether PAK2 modulates the cell cycle progression as well
as the suppression of apoptosis in response to IGF-1 sti-
mulation. IGF-1 promoted cell-cycle progression (G2/M
and S phase) under 4OHT/E2 antagonizing condition,
which was suppressed by shPAK2 (Fig. 6f and Supple-
mentary Fig. 8A). This suppression coincided with an onset
of apoptosis evidently at late time point, which also
occurred under 4OHT/E2 (Fig. 6g and Supplementary Fig.
8B). We further evaluated this antiapoptotic effect of PAK2
Fig. 5 PAK signaling in response
to IGF-1 stimulation and inter-
action with IGF-1 signaling net-
work. a Quantitative SILAC-
based phospho-proteomics
scheme of MCF7/IGF1R cells
under IGF-1 stimulation. Par-
ental MCF7 cell line was taken
as control. IGF-1, 100 ng/ml, 30
min. b IPA reported phosphory-
lated components in IGF-1 and
PAK signaling pathways. Phos-
phorylation level was given as
ratio of IGF-1 stimulated
(“Medium” labeling) to non-
stimulated (“Heavy” labeling)
MCF7/IGF1R cells. c IPA map-
ped interaction of phosphory-
lated components in IGF-1 and
PAK signaling networks. Com-
ponents in red, cross-talking in
IGF-1 and PAK signaling
networks
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on IGF1R-mediuated resistance to 4OHT in a 3D culture
system. While shCtrl cells formed acini under resistance
condition, shPAK2 sufﬁciently abolished the resistant aci-
nar outgrowth (Fig. 6h and Supplementary Fig. 8C).
IGF1R-mediated antiestrogen resistance involves
PAK2/PIX survival components
PAK2 drives PAK-interacting exchange factor (PIX) acti-
vation in modulating cell migration and protrusion, pro-
moting cell growth and survival, and preventing apoptosis
[28, 32–34]. As a Rac effector, PAK2 is also essential for
the activation of β-catenin [35], and the cell-cell adhesion
protein β-catenin has been shown to mediate IGF-1/IGF1R
action in cell proliferation [36]. We found that over-
expression of IGF1R in MCF7 cells led to reduced cell-cell
junctions (Supplementary Fig. 9A) and conferred a scat-
tering phenotype in IGF-1 stimulation, which was dimin-
ished by shPAK2 (Fig. 7a). SILAC spectra revealed
increased phosphorylation levels of PIXα/β (also named
Rac/Cdc42 guanine nucleotide exchange factor 6/7, ARH-
GEF6/7) (Fig. 5b and Fig. 7b) as well as β-catenin (Sup-
plementary Fig. 9E) after IGF-1 stimulation. Membranous
staining of the cell–cell adhesion marker E-cadherin showed
that silencing of PAK2, PIXα/β or β-catenin inhibited the
IGF1-mediated cell scattering phenotype (Fig. 7c and
Supplementary Fig. 9B) and blocked IGF-1-modulated cell
protrusion signiﬁcantly (Fig. 7d). Furthermore, targeting
PIXα, PIXβ or β-catenin (Fig. 7e) recovered the sensitivity
of MCF7/IGF1R cells to antiestrogens 4OHT and FUL
(Fig. 7f), as did siPAK2, in dose-dependent manners
(Supplementary Fig. 9C and D). The effect of PAK2 was
not limited to MCF7/IGF1R cells. Parental MCF7 cells
express low level of endogenous IGF1R (Supplementary
Fig. 1A) and demonstrate a limited IGF-1-mediated anti-
estrogen resistance (Supplementary Fig. 1B). Yet, impor-
tantly, also silencing of PAK2, PIXα, PIXβ or β-catenin in
parental MCF7 decreased the proliferation under 4OHT or
FUL, E2, and IGF-1 resistance conditions (Supplementary
Fig. 9F). The involvement of PAK2 (but not other PAK
family members), PIXα/β and β-catenin in IGF1R-mediated
antiestrogen resistance was also conﬁrmed in T47D/IGF1R,
another established ER+ breast cancer cell line with ectopic
IGF1R overexpression (Supplementary Fig. 10A-E). Simi-
lar to siPAK2, siPIXα, siPIXβ or β-catenin did not restrict
IGF-1-stimulated AKT and ERK phosphorylation in both
MCF7/IGF1R (Fig. 7g) and T47D/IGF1R cell lines (Sup-
plementary Fig. 10F). While PAK1 has been shown to
stabilize β-catenin [37], depletion of PAK2 did not affect β-
catenin expression levels in neither MCF7/IGF1R (Fig. 7h)
nor T47D/IGF1R (Supplementary Fig. 10G). Of relevance,
IGF-1-induced PIXβ phosphorylation was downstream of
IGF1R/PAK2 signaling, as siPAK2 inhibited the phos-
phorylation of PIXβ in IGF-1 stimulation in both resistant
cell lines (Fig. 7h and Supplementary Fig. 10G). These data
indicate PAK2/PIX signaling as a distinct signaling branch
downstream of IGF1R activation. Importantly, the PAK2/
PIX-mediated antiestrogen resistance after IGF1R signaling
seems to be a general phenomenon.
PAK2 expression is associated with
clinicopathological characteristics and progression
free survival
Our clinical dataset of 101 MBC patients treated with ﬁrst-
line tamoxifen revealed that PAK2 RNA expression level
predicated high HR in disease progression (Fig. 2a) and
poor outcome as veriﬁed in Kaplan-Meier survival curve
(Fig. 4a). To further assess the clinical relevance of PAK2,
we next performed a PAK2 tissue microarray (TMA)
staining in 291 patients with primary operable ER+ breast
cancer who subsequently developed MBC after ﬁrst-line
tamoxifen and for which detailed clinical follow-up was
available [38]. TMA results showed that PAK2 protein
staining was detected primarily in cytoplasm in 242 of the
291 ER+ tumors (83%). The quantity of positive cells was
indistinguishable, since almost all tumor cells within the
evaluated biopsy cores were PAK2 positive. Staining
intensity separated the specimens into 114 with weak
staining (47%), 92 with moderate staining (38%), and 36
with strong staining (15%) tumors (Fig. 8a, b). No sig-
niﬁcant associations were observed between PAK2 intensity
and traditional predictive factors, including age and meno-
pausal status at start of therapy, lymph nodes involved,
Fig. 6 PAK2 is activated apart from PI3K/AKT and MAPK/ERK
pathways and promotes cell-cycle progression and anti-apoptosis in
IGF1R-mediated antiestrogen resistance. a Ingenuity pathway analysis
of SILAC phospho-proteomic data diagramed phosphorylated pro-
teins/kinases (in red circles) in IGF-1/IGF1R signaling pathway.
Tamoxifen resistance inducers were indicated (blue). The known
relations of PAK2 to PI3K-AKT and GRB2-Raf-ERK downstream of
IGF1R pathway were connected (yellow lines). b SILAC phospho-
proteomics identiﬁed a high phosphorylation of PAK2 at Ser141 in
IGF-1 stimulated MCF7/IGF1R cells. Peaks colored in gray, blue and
brown represent the phosphopeptides from light-, medium- and heavy-
isotope labeled cells, respectively. c PAK2 phosphorylation in MCF7/
IGF1R cells in time course exposure to IGF-1 (100 ng/ml). d PAK2
phosphorylation status under inhibitory condition of IGF1R kinase
inhibitor BMS-536924, MEK inhibitors U0126, PD-184352 and
AZD6244, or PI3K inhibitors BEZ235 and PI-103, in IGF-1 stimu-
lated MCF7/IGF1R cells. e IGF-1 induced phosphorylation of AKT
and ERK in siPAK2 and shPAK2 depletion. f Flow cytometry sorting
of cell proportions in cell-cycle G1/G0, G2/M and S phases in shCtrl
and shPAK2 cells under 4OHT+ E2 antagonizing versus 4OHT+ E2
+ IGF-1 resistant condition. g Annexin V apoptotic fractions in shCtrl
and shPAK2 cells under the 4-day treatments as indicated. Values
were derived from triplicate samples. Data were expressed as mean±
SD. h 3D culture showing acini formation of shCtrl and shPAK2 cells
in 14 days responding to indicated treatments. Image× 20
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Fig. 7 Involvement of PAK2 survival signaling components PIXα/β in
IGF1R-mediated antiestrogen resistance. a shPAK2 eliminated IGF-1-
stimulated scattering phenotype of MCF7/IGF1R cells. IGF-1, 100 ng/
ml, 30 min. b SILAC spectra graph showed a PIXα/β phosphopeptide
with high intensity in IGF-1 stimulated MCF7/IGF1R cells. c siPAK2,
siPIXα, siPIXβ and β-catenin (β-cat) inhibited cell protrusion of IGF-
1-stimulated MCF7/IG1R cells, compared to siCtrl. d Quantiﬁcation
of cell protrusion under indicated silencing in response to IGF-1 sti-
mulation. Around 400 cells were counted. Image× 60. e siRNA
knockdown of PIXα, PIXβ and β-catenin in MCF7/IGF1R cells.
f Targeting of PIXα, PIXβ and β-catenin re-sensitized MCF7/IGF1R
cells to anti-estrogenic effect of 4OHT and FUL, as did siPAK2.
Proliferation values were relative to siCtrl under DMSO control.
Values were derived from triplicate samples. Data were expressed as
mean± SD. Signiﬁcance was determined using a two-sided Student’s
t-test. *** P< 0.01. g Similar to siPAK2, siPIXα, siPIXβ and siβ-cat
did not interfere with phosphorylation of AKT and ERK by IGF-1
stimulation. h PIXβ phosphorylation downstream PAK2 in IGF-1
stimulation
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histology, dominant site of relapse, disease-free interval,
and the fraction of ER, PgR, and HER2/neu-positive cells
(Supplementary Table 2 and Table 3). There was only a
signiﬁcant relationship with the fraction of HER2/neu-
positive cells. Strong PAK2 staining was signiﬁcantly
associated with PFS in univariate analysis (HR 1.77, 95%
CI 1.13–2.78, P= 0.013) (Figs. 8b, c and Supplementary
Fig. 11A and B). In multivariate analysis, PAK2 strong
staining was related with PFS (HR 1.87, 95% CI 1.18–2.96,
P= 0.008) (Fig. 8b and Supplementary Fig. 11A and B),
when compared to tumors with no PAK2 expression and
corrected for the traditional predictive factors.
PAK2 staining was not related with overall survival (weak:
HR= 1.03, 95% CI 0.71–1.49, P= 0.890; weak/moderate:
HR= 0.99, 95% CI 0.67–1.46, P= 0.972; strong: HR=
1.19, 95% CI 0.73–1.93, P= 0.479). These data indicated
that high PAK2 expression in MBC patients associates with
unfavorable outcome after ﬁrst-line tamoxifen, strongly
suggesting the important clinical correlation of PAK2 to the
development of tamoxifen resistance.
Discussion
Our kinome screen of IGF1R-mediated tamoxifen resis-
tance has deﬁned 10 hits with clinical relevance to ER+
MBC patients treated with ﬁrst-line tamoxifen monotherapy
[23, 24]. Among tamoxifen resistance suppressors, CDK10
was previously deﬁned as a determinant for tamoxifen
resistance [39], while BMPR1B, CDK5, EIF2AK1, and
MAP2K5 are unknown players. The tamoxifen resistance
inducer CHK1 has been associated with an impaired
tamoxifen response [40], while the implication of PAK2,
RPS6KC1, TTK, and TXK in antiestrogen resistance has not
been reported yet. Low expression of the suppressors, or
enhanced expression of the inducers, as individual markers,
might contribute to developing antiestrogen resistance,
thereby leading to poor disease outcome. PAK2, as well as
RPS6KC1, modulates the proliferation of resistant cells in
an IGF1R-signaling dependent manner, suggesting their
potency as novel targets in IGF1R-mediated antiestrogen
resistance.
Fig. 8 Relevance of PAK2 expression in primary tumor specimens to
poor outcome of metastatic breast cancer patients after ﬁrst-line
tamoxifen. a Representative tissue cores with IHC staining of PAK2
protein, showing negative, weak, moderate and strong cytoplasmic
PAK2 staining intensity. Scorings were performed at lower magniﬁ-
cation images. b Cox uni and multivariate analysis for PFS of PAK2
protein expression levels in 291 ER+ primary tumor specimens of
MBC patients treated with ﬁrst-line tamoxifen therapy. c Kaplan-
Meier curve for PFS as function of PAK2 staining intensity in 291 ER
+ primary tumors of MBC patients treated with ﬁrst-line tamoxifen.
Patients were divided into three groups according to their staining
intensity in negative (blue line), in weak/moderate (red line), and in
strong staining (green line). Patients at risk at different time points
were indicated
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PAK2 belongs to p21 protein (Cdc42/Rac)-activated
kinase (PAKs) family that consists of six members. PAK
expression and activity are often upregulated in human
tumors [28, 41]. PAK1 expression is related to tamoxifen
response [42, 43]. We report here that PAK2 expression is
signiﬁcantly predictive for unfavorable outcome in two
cohorts of 101 and 291 ER+MBC patients with ﬁrst-line of
tamoxifen monotherapy, but not in 221 ER+ LNN breast
cancer patients without any adjuvant systemic treatment,
stressing the clinicopathological correlation of PAK2 to the
development of antiestrogen resistance in luminal breast
cancer. PAK2 staining intensity was evaluable for 291 ER+
primary tumor specimens in our clinical retrospective set-
ting. Recently, a multi-parametric serum marker panel was
reported to distinguish breast cancer from healthy control
groups. However, the auto-antibodies of this panel,
including PAK2, as an individual marker, displayed relative
weak discriminatory performance [44]. In our study, almost
all tumor cells had some level of PAK2 staining in the
majority of tested specimens. Therefore, standard immu-
noreactive scoring methods combining percentage positive
cells with intensity [38] are not appropriate, and also not
always applied. For instance, ER and PR in breast cancer
are only evaluated for the proportion of positive tumor cells
and not for their staining intensities. Rather, we found that
analysis of PAK2 staining intensity would be a relevant
approach for selection of patients for tamoxifen treatment.
Since our cohort differed in the number of cases with regard
to staining intensities and the low magniﬁcation images
showed that strong PAK2 staining was clearly distinguish-
able from the other intensities, only intensity was further
evaluated. Our univariate and multivariate analyses showed
that strong PAK2 staining was related to progression free
survival, also independent from traditional factors. Thus our
study demonstrated strong PAK2 staining in primary breast
tumors of especially patients resistant to tamoxifen of the
advanced disease setting.
PAKs play pivotal roles in motility, proliferation, mitosis
and survival that are required for oncogenesis [28, 45, 46].
Tumor cells with upregulated PAKs tend to become
dependent on PAK signaling. It has been uncovered that
PAKs interact with downstream β-catenin to promote
growth signaling [37, 47]. PAKs have been placed down-
stream of PI3K/AKT [45] and upstream of MAPK/ERK
canonical cascades [46]. And crosstalk occurs within ERK/
AKT and β-catenin signaling networks in cell cycle pro-
gression [48, 49]. Our results implicate PAK2/PIX and β-
catenin in IGF-1/IGF1R signaling, in a manner that is
separate from PI3K/AKT and MAPK/ERK activation.
Similar ﬁndings have been reported for KRAS-driven pro-
liferation of colon cancer cells [29]. The interaction between
PAKs and ERK is complicated. In ﬁbroblast growth factor
stimulation, PAK2 is activated downstream of ERK [50],
while PAK activity controls ERK activation in the context
of platelet derived growth factor but not epidermal growth
factor signaling [51]. Moreover, ERK and AKT activity
have been reported to be regulated by distinct PAK family
members [52]. Clearly, PAKs regulate and mediate signal-
ing cascades in a highly context-dependent manner in
response to different stimuli.
Activation of PAK/PIX components conveys oncogenic
signaling to promote cell growth and survival, cell migra-
tion and invasion, and prevent apoptosis [28, 32–34, 53,
54]. Our results demonstrate that PAK2 and PIXα/β act
downstream of IGF1R signaling to mediate antiestrogen
resistance in breast cancer cells. Silencing of PAK2 or
PIXα/β attenuates the IGF-1-induced migratory and resis-
tant phenotypes, suggesting that targeting PAK2/PIX sur-
vival signaling may provide a novel therapeutic avenue for
antiestrogen resistant luminal ER+ breast cancers. Future
work must be aimed at the identiﬁcation of pharmacological
inhibitors targeting this axis to overcome resistance against
antiestrogen therapy in luminal ER+ breast cancer.
Materials and methods
High-throughput kinase and phosphatase siRNA
screen and data analysis
We performed the high-throughput screen on a Biomek FX
(Beckman Coulter) liquid handling system under indicated
conditions (Supplementary Fig. 2). The primary screen was
carried out by use of SMARTpool siRNAs targeting human
genome-wide 779 kinases and 193 phosphatases (Dharma-
con, Thermo Fisher). Each primary screen plate included
positive and negative siRNA controls. In the validation
screen, SMARTpool siRNA and single siRNA_1, _2, _3
and _4 that comprise the SMARTpool mix were used to
target each candidate hit. For siRNA transfection, 15,000
cells per well were seeded in 96-well plate overnight,
transfected for 2 days in replica cell plates (Replica 1 & 2)
with 50 nM siRNA divided from the siRNA transfection
plate by use of DharmaFECT 4 transfection reagent
(Dharmacon, Thermo Fisher) in 5% charcoal-dextran trea-
ted FBS (CDFBS) starving medium, and proliferated for
4 days under indicated condition. The sulforhodamine B
(SRB) colorimetric assay was used as read-out for cell
proliferation [14]. Primary screen data were analyzed using
an unbiased sample-based analysis [55]. Brieﬂy, raw SRB
absorbance values of individual siRNA samples in each
plate were transformed into Z scores by the formula “Z
score= (individual siRNA sample—mean of all siRNA
samples)/standard deviation of all siRNA samples”. Vali-
dation screen data were assessed with a non-targeting
control-based Z score analysis by the formula “Z score=
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(individual siRNA sample—mean of negative controls)/
standard deviation of negative controls”. We took Z> |
mean ± 1.5× SD| and P< 0.05 as signiﬁcant effect.
Antibodies and compounds, 3D culture, Western
blot assay, and immunoﬂuorescence staining
Mouse antibody speciﬁc for PAK2 (#4825) and rabbit
antibody against phospho-PAK1 (Ser144)/PAK2(Ser141)
(#2606) were purchased from Cell Signaling, mouse anti-
body against E-cadherin (6101810) from BD Transduction,
mouse antibody against β-PIX (611648) from BD Bios-
ciences, and rabbit antibody against α-PIX (HPA003578)
from Sigma. For other antibodies and compounds, and
assays used, they were referred to those as previously
described [14].
shRNA knockdown of PAK2
To establish shRNA-mediated PAK2 knockdown, we used
two pLKO.1-puro lentiviral plasmids containing validated
human PAK2 shRNA Seq1 (TRCN0000002115; Region:
3UTR; sequence: CCGGCTCTAGGAACCAAAGTGA
TTTCTCGAGAAATCACTTTGGTTCCTAGAGTTTTT)
or Seq2 (TRCN0000194671; region: CDS; sequence:
CCGGCGGGATTTCTTAAATCGATGTCTCGAGACA
TCGATTTAAGAAATCCC GTTTTTTG) (Sigma-Aldrich;
in collaboration with Dr. Rob Hoeben). The PAK2 shRNA
lentiviral plasmid was co-transfected with the packaging
constructs pMDLg/pRRE, pRSV-Rev and pCMV-VSV-G
by Lipofectamine 2000 (Invitrogen) into human
HEK293T cells cultured in 10% FBS DMEM (GIBCO).
The lentiviral particles were freshly harvested and trans-
duced into MCF7/IGF1R cells [14]. The stable shRNA-
mediated PAK2 knockdown MCF7/IGF1R cell lines were
selected with puromycin and named MCF7/IGF1R
shPAK2_1 and shPAK2_2, respectively. The shRNA con-
trol (shCtrl) pLKO.1-puro plasmid (SHC002, Sigma) tar-
geting no known mammalian DNA was used to establish
control cell line MCF7/IGF1R shCtrl.
pcDNA-PAK2 AMAXA transfection
The pcDNA3.1(+) vector containing hygromycin resistance
gene (pcDNA-hygro) and pcDNA-hygro-PAK2 containing
human PAK2 cDNA (pcDNA-PAK2) were kindly provided
by Dr. Claude Backendorf (Leiden University, The Neth-
erlands). Transient transfection of the pcDNA-hygro or
pcDNA-PAK2 into MCF7/IGF1R shPAK2 cell lines was
carried out by use of AMAXA Nucleofector® Kit V
(LonzaBio) under program E-014.
Quantitative SILAC-based phospho-proteomics of
MCF7/IGF1R cells under IGF-1 stimulation
To elucidate the signaling networks assembled by IGF-1R
directly after receptor activation in MCF7/IGF1R cells in
more detail, we initiated a global phospho-proteomic ana-
lysis using stable-isotope labeling by amino acids in cell
culture (SILAC) [56, 57]. Brieﬂy, SILAC labeling was
performed in parallel, as schemed (Fig. 5a). “Light” labeling
with L-[12C6,14N2]lysine (Lys0) and L-[12C6,14N4]argi-
nine (Arg0), “medium” labeling with L-[2H4]lysine (Lys4)
and L-[13C6]arginine (Arg6), and “heavy” labeling with L-
[13C6,15N2]-lysine (Lys8) and L-[13C6,15N4]arginine
(Arg10) were used as triple encoding SILAC conditions.
After 5 or 7-cell doublings in SILAC culture, the “medium”
(Lys4, Arg6) labeled MCF/IGF1R cells were starved in
0.5%FBS medium overnight and then SFM for 2 hours,
followed by 30-min IGF-1 (100 ng/ml) stimulation. “Heavy”
(Lys8, Arg10) labeled MCF7/IGF1R cells were left non-
stimulated. Parental MCF7 cells were cultured as control
with “light” labeling. Then all differentially labeled cells
were washed twice with ice-cold 0.5× PBS (diluted with
sterile H2O) and then lysed with a buffer containing 4%
SDS, 100mM Tris-HCl (pH 7.8) and 0.1 M DTT in H2O
and harvested into sterile polypropylene reaction tubes. For
phosphopeptide identiﬁcation and quantitation by High-
Performance Liquid Chromatography (HPLC) and Mass
Spectrometry (MS), equal amount of protein (1:1:1) from
each SILAC condition was mixed following trypsin diges-
tion according to the ﬁlter aided sample preparation proto-
col [58] and peptide fractionation by strong cation exchange
chromatography, followed by titanium-dioxide phosphor-
peptide enrichment [59]. MS analysis was performed on the
LTQ-Orbitrap Velos mass spectrometer with high-energy
collisional dissociation fragmentation. Raw MS ﬁles were
analyzed with MaxQuant.
Flow cytometry cell cycle assay
Cells (200,000/well) were seeded in 12-w cell plate over-
night, starved for 2 days in 5% CDFBS medium, and then
treated under drug conditions as indicated. The time after 2-
day starvation and before drug treatment was considered to
be Day 0. Cells were then harvested after 4-day treatment,
ﬁxed with cold 100% ethanol and labeled in staining
solution containing 10μM propidium iodide (PI) and 50 ng/
ml RNase A (BD CycletestTM Plus DNA Reagent Kit, BD
Biosciences). Cells were analyzed by use of FACSCanto II
ﬂow cytometer (BD Biosciences). The percentage of cells in
G0/G1, S and G2/M phases were determined from 10,000
ungated cells (cell events) using the FACSDiva Software
v6.1.2 (BD Biosciences).
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Annexin V apoptosis assay
To detect apoptosis, a live cell imaging of Annexin V-
Alexa633 labeling was performed in real time, as described
previously [60]. Brieﬂy, 10,000 cells/well were seeded in
96-well plate. Following 2-day starvation in 5% CDFBS
medium, cells were treated as indicated and labeled with
Annexin V-Alexa633 (250 ng/ml) that conjugates to phos-
phatidyl serine on the membranes of apoptotic cells. At the
time points of day 0, 1, 2, 3, and 4, the Annexin V in-taken
cells were captured under Cy5 channel and the whole cell
population was imaged under transmitted light by use of BD
pathway 855 imager (Becton Dickinson). Simultaneously,
the nuclei of live cells were stained with DNA dye Hoechst
33342 (200 ng/ml) and imaged for cell density. The number
of Annexin V positive cells and the total cell number in
each well were quantiﬁed using Image Pro (Media Cyber-
netics, Bethesda, MD, USA). Annexin V apoptosis fraction
was calculated by normalization of Annexin V positive cells
to the total cell number.
Experimental statistical analysis
Each average value was derived from triplicate experi-
mental samples. Statistical analysis of all experimental data
was performed using a two-sided Student’s t-test. Data were
expressed as mean± SD. Signiﬁcance was set at P< 0.05.
Ethics statement
The retrospective studies were approved by the medical
ethics committee of the Erasmus MC Rotterdam, the
Netherlands (MEC 02.953) and included coded fresh frozen
and/or formalin-ﬁxed, parafﬁn-embedded primary breast
tumor tissue specimens from patients with primary operable
breast cancer between 1985 and 2000. It was carried out
according the Code of Conduct of the Federation of Medical
Scientiﬁc Societies in The Netherlands (http://www.fmwv.
nl) and reported, wherever possible, following the
REMARK guidelines [61].
Patients gene expression data
Patients with primary operable breast cancer were included
in study who subsequently developed MBC treated with
ﬁrst-line tamoxifen and for which detailed clinical follow-
up was available. For the gene expression microarray ana-
lyses, a cohort of 101 patients was investigated. This cohort
has already been described by us previously [24]. The tissue
microarray analyses used a cohort of 250 patients that has
been described by us [38], but includes now 41 additional
patients. Brieﬂy, for 291 of the 378 available patients ER-
positive tumor core biopsies of the breast TMA were
selected for further analyses. Of these 291 patients, 128
(44%) patients underwent breast conserving surgery and
163 modiﬁed mastectomy (56%). Median follow-up time
after start therapy for patients alive was 42 months (range
6–188 months). All patients received ﬁrst-line tamoxifen,
and of these were 174 patients (60%) hormone-naïve and
117 patients (40%) received adjuvant chemotherapy.
Response to therapy was observed in 181 patients (62%)
whereas 110 patients (38%) did not have clinical beneﬁt.
The patients with response included 7 patients (4%) with
complete response, 50 patients (28%) with partial response
and 124 patients (68%) with stable disease for more than six
months.
Patient tissue microarrays and immunohistological
evaluation
Tissue microarrays of all formalin-ﬁxed, parafﬁn-embedded
primary breast tumor specimens were prepared and immu-
nohistochemically stained according to the procedures
described previously [38]. The staining was performed with
the primary mouse monoclonal antibody against PAK2 and
incubated for 1 hour (1:50 dilution) after 40 min antigen
retrieval at pH9.0. Subsequently, TMA slides were incu-
bated with a secondary antibody and staining was visualized
using diaminobenzidine. PAK2 protein staining was scored
for quantity and intensity by two independent observers,
using Slidepath software (Leica Biosystems, Dublin). For
the web-based scoring, stained TMAs were digitalized by a
Hamamatsu Nanozoomer 2.0 HT (Hamamatsu photonics,
Hamamatsu, Japan at magniﬁcation× 20 (0.45 μm/pixel
resolution). Staining was grouped according to standardized
categories for the estimated percentage of PAK2 positive
cells (0%, 1–4% positive cells, 5–10%, 11–20%, 21–30%,
31–40%, 41–50%, 51–99%, 100%) and staining intensity as
exempliﬁed in Fig. 8a (negative, weak, moderate, strong).
More information for patients, ethics statement, data ana-
lysis and statistical methods, see supplemental information.
Patient data analysis and statistics
Statistical analyses were performed with STATA statistical
package, release 13.0 (STATA Corp., College Station, TX,
USA). Pearson’s chi-squared, Mann–Whitney U tests, and
Fisher’s exact test were used to investigate the association
between PAK2 protein expression and clinicopathological
factors. HR with 95% CI was computed by the Cox pro-
portional hazard model to assess the relationship between
PAK2 protein expression and PFS after ﬁrst-line therapy
with tamoxifen. The endpoint PFS was deﬁned as the time
elapsed between start of tamoxifen therapy and the ﬁrst
detection of disease progression or death, whatever came
ﬁrst during treatment [38]. A multivariate analysis was
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performed to determine whether PAK2 expression had
predictive value and was independent when added to base
model of clinicopathological factors. Survival curves were
generated by the Kaplan-Meier method. The log-rank test
and log-rank test for trends were used to test for differences
between survival curves. The P-values were two sided and
P< 0.05 was considered as statistically signiﬁcant.
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